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Synaptic AMPA receptors (AMPARs) are regulatedby
a family of auxiliary subunits known as transmem-
brane AMPA receptor regulatory proteins (TARPs).
TARPs control the trafficking and gating of AMPARs.
However, the number of TARP molecules that
assemble within individual AMPAR channels is
unknown.Here,we covalently linkAMPARs to TARPs
to investigate the properties of TARP/AMPAR com-
plexes with known stoichiometry in HEK cells. We
find that AMPARs are functional when associated
with four, two, or no TARPs, and that the efficacy of
the partial agonist kainate varies across these condi-
tions, providing a sensitive assay for TARP/AMPAR
stoichiometry. A comparison of these results with
data obtained from hippocampal neurons demon-
strates that native AMPARs associate with TARPs
with a variable stoichiometry that depends on TARP
expression level. Interestingly, AMPARs in hippo-
campal pyramidal neurons are saturated by TARP
expression, while those in dentate gyrus granule
neurons are not, indicating that variable TARP/AM-
PAR stoichiometry provides a mechanism for cell-
type-specific regulation of AMPAR function.
INTRODUCTION
Glutamate, the main fast excitatory neurotransmitter in the CNS,
acts primarily on two types of ionotropic receptors: NMDA
receptors (NMDARs) and AMPA receptors (AMPARs). Activation
of AMPARs by synaptic glutamate results in fast moment-to-
moment depolarization of postsynaptic neurons, a process
crucial for information propagation in the CNS. AMPAR subunits
form ion channels by assembling as heterotetramers of GluA1–
GluA4 (GluR1–GluR4 or GluR-A–GluR-D) (Collingridge et al.,
2008; Dingledine et al., 1999; Hollmann and Heinemann, 1994;
Mayer and Armstrong, 2004; Seeburg, 1993). In addition to these
principal subunits, native AMPARs also associate with auxiliary
subunits known as TARPs (Chen et al., 2000; Nicoll et al.,
2006; Osten and Stern-Bach, 2006; Ziff, 2007). There are fourclassical TARPs in the CNS: g-2, g-3, g-4, and g-8 (Tomita
et al., 2003). These molecules associate with all four GluAs and
regulate their trafficking, gating, and pharmacology in a TARP-
subtype-specific manner (Milstein and Nicoll, 2008; Nicoll
et al., 2006; Osten and Stern-Bach, 2006; Ziff, 2007). While
most neurons express more than one TARP subtype, cerebellar
granule neurons are unique in that they only express g-2.
Accordingly, cultured granule neurons from the mutant mouse
stargazer, which lack functional g-2 protein, have been used as
a model system to understand TARP function (Chen et al.,
2000; Cho et al., 2007; Milstein et al., 2007). Loss of g-2 in these
neurons abolishes surface and synaptic AMPAR expression
(Chen et al., 2000; Hashimoto et al., 1999). Similar phenotypes
result from the loss of TARP family members in other neuronal
cell types as well (Menuz et al., 2008; Rouach et al., 2005). There-
fore, TARPs are believed to be necessary for AMPAR membrane
trafficking and synaptic targeting throughout the brain.
An important unanswered question in the field concerns the
stoichiometry of the association between TARPs and AMPARs.
We previously demonstrated that the decay kinetics of synaptic
AMPARs varies with the expression level of TARP g-2 in cere-
bellar granule neurons, suggesting a variable TARP/AMPAR stoi-
chiometry (Milstein et al., 2007). However, it was not possible to
determine the exact stoichiometry from these data; the result
could have been produced by mixed populations of AMPARs
with anywhere from zero to four associated TARPs. To address
whether a variable number of TARPs can assemble with AM-
PARs, one needs a technique that allows the number of TARPs
on individual AMPARs to be counted unambiguously. To this
end we have constructed fusion proteins between GluA subunits
and TARPs. By coexpressing in HEK cells combinations of
GluA1 and GluA2 with and without fused TARPs, we have suc-
ceeded in titrating the number of TARPs bound to AMPARs,
producing functional AMPAR complexes with zero, two, and
four bound TARPs. Importantly, the relative efficacy of the partial
agonist kainate, which is known to increase with TARP associa-
tion (Tomita et al., 2005; Turetsky et al., 2005), proved to be
a particularly sensitive measure of TARP/AMPAR stoichiometry.
When compared with these expression data, the efficacy of kai-
nate on endogenous AMPARs from hippocampal neurons is
consistent with the binding of multiple TARPs per native AMPAR.
Furthermore, relative differences in TARP expression level
produce different TARP/AMPAR stoichiometries in two different
neuronal cell types, CA1 pyramidal neurons and dentate gyrusNeuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc. 633
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TARP/AMPAR Stoichiometrygranule neurons. Finally, we found that, in addition to kainate effi-
cacy, deactivation and desensitization kinetics of AMPARs vary
with TARP expression level in CA1 pyramidal neurons. This
variation in stoichiometry broadens the ways in which TARPs
modulate AMPAR function in the brain.
RESULTS
Kainate Efficacy Is Enhanced by Fusion or Coexpression
of GluA1 and g-2
To fix the number of TARPs associated with individual AMPARs,
we fused the full-length GluA1 to the N terminus of TARP g-2 with
a short linker sequence (Figure 1A1). If these receptors assemble
and form functional channels expressed on the cell surface, they
will contain four TARPs. When expressed in HEK cells, outside-
out patches containing the fusion construct A1g-2 produced
sizeable currents in response to application of 1 mM glutamate
(Figure 1A2), demonstrating that these channels are properly
Figure 1. Kainate Efficacy Is Enhanced by Coexpres-
sion or Fusion of TARPs with GluA1
(A1) Construction of GluA-TARP fusion proteins. The full-
length GluA was fused to the N terminus of TARPs with a short
segment of linker sequence. (A2) Glutamate- (Glu, 1 mM)
induced currents in an outside-out patch excised from an
HEK cell transfected with GluA1 fused to TARP g-2 (A1g-2),
indicating that this construct forms functional channels. The
currents were recorded in presence of 100 mM of cyclothia-
zide. (B) Kainate- (KA, 1 mM) and glutamate- (Glu, 1 mM)
induced currents in an outside-out patch excised from a cell
transfected with A1g-2. On the sample patch, kainate-induced
current was 49% of that of glutamate. The kainate-to-gluta-
mate ratio (IKA/IGlu) is referred to as the kainate efficacy. (C)
When cells were transfected with only GluA1 (A1), kainate-
induced currents were 5% of that of glutamate in the sample
patch. (D) Coexpression of GluA1 and g-2 produced a similar
kainate efficacy to that of the fusion protein A1g-2. (E–G) Kai-
nate efficacy was similar in fusion constructs A1g-3, A1g-4,
and A1g-8. Scale bar: 2 s, 100 pA. Between slashed lines
was 11.5 s. (H) Summary of kainate efficacy in GluA1 homo-
meric receptors with or without TARPs. GluA1, 7.4% ±
1.1%, n = 10; GluA1+g-2, 54.9% ± 1.9%, n = 10; A1g-2,
52.7% ± 2.1%, n = 10; A1g-3, 54.8% ± 2.5%, n = 7; A1g-4,
58.8% ± 2.4%, n = 6; GluA1+g-8, 57.1% ± 3.0%, n = 8;
A1g-8, 53.1% ± 3.5%, n = 9. In GluA1+g-2 experiment, the
DNA ratio used in transfection was GluA1:g-2 = 2:3. In
GluA1+g-8 experiments, 2:3 DNA ratio appeared insufficient
for forming saturating TARP/AMPA stoichiometry. The data
used here were pooled from GluA1:g-8 = 1:5 and 1:10
(Figure S1). Error bars = SEM.
folded, traffic to the plasma membrane, and appro-
priately gate in response to glutamate. In order to
determine whether the fused TARP molecules are
functionally associated with the AMPAR channel,
we took advantage of the fact that TARP associa-
tion increases the efficacy of the partial agonist
kainate (Tomita et al., 2005; Turetsky et al., 2005).
Indeed, A1g-2 (Figures 1B and 1H) responded to
1 mM kainate application with substantially larger
currents than those produced by GluA1 alone
(Figure 1C and 1H), demonstrating that the fused TARP mole-
cules interact with the AMPAR channel and modulate the effi-
cacy of kainate. We assayed kainate efficacy of expressed
AMPARs by measuring the ratio of currents induced by kainate
relative to glutamate (IKA/IGlu). Fusion of GluA1 to g-2 (A1g-2)
increased kainate efficacy in a manner similar to coexpression
of nonfused GluA1 with g-2 (Figures 1D and 1H). We also
measured the kainate efficacy of channels produced by fusion
of GluA1 with the other TARP family members (g-3, g-4, and
g-8). Each of these fusion constructs, A1g-3 (Figure 1E), A1g-4
(Figure 1F), and A1g-8 (Figure 1G), produced indistinguishable
kainate efficacies (Figure 1H). While some previous studies co-
expressing GluAs and TARPs showed differences in kainate effi-
cacy for different TARPs (Cho et al., 2007; Korber et al., 2007;
Kott et al., 2007; Tomita et al., 2005), no difference was seen in
kainate efficacy across TARPs expressed in stargazer cerebellar
granule neurons (Milstein et al., 2007). Furthermore, we found in
this set of experiments that the IKA/IGlu observed in HEK cells634 Neuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc.
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TARP/AMPAR StoichiometryFigure 2. Glutamate- and Kainate-Induced
Currents from GluA1/2 Receptors Ex-
pressed in HEK Cells
(A–H) Examples of currents in outside-out
patches. The cDNA of GluA1 with or without linked
TARPs was overnumbering GluA2s (3:2). Scale
bar: 2 s, 100 pA. (I) Summary of kainate efficacy
in GluA1/2 receptors expressed in HEK cells.
Note that without TARPs, GluA1/2 had low kainate
efficacy (A1+A2, 9.3% ± 0.7%, n = 7). Fusion
receptors containing four TARPs had increased
kainate efficacy. A1g-2+A2g-2, 50.3% ± 2.5%,
n = 10; A1g-8+A2g-8, 48.2% ± 1.5%, n = 8. Coex-
pression of TARP g-2 with GluA1/2 had high kai-
nate efficacy (A1+A2+g-2, 52.8% ± 1.3%, n = 5).
The kainate efficacy was intermediate in two-
TARP channels. A1g-2+A2, 31.8% ± 1.3%, n = 9;
A1+A2g-2, 28.7% ± 2.8%, n = 9; A1g-8+A2,
34.3% ± 2.1%, n = 7; A1+A2g-8, 30.7% ± 2.6%,
n = 7. Error bars = SEM. (J) Kainate efficacy did
not vary with variable ratios of A1g-2 and GluA2
in coexpression. When A1g-2 and GluA2 were co-
transfected in a ratio of 20:1, kainate efficacy
(32.1% ± 2.2%, n = 5) was not higher than that in
a ratio of 3:2 (31.8% ± 1.3%, n = 9). When A1g-2
and GluA2 were expressed in a ratio of 1:20,
kainate efficacy was not significantly changed
(25.6% ± 1.5%, n = 8, p = 0.12 compared to
3:2 group). All currents in this figure were recorded
in the presence of 100 mM cyclothiazide. PhTx
(600 nM–10 mM) was included in the solutions
to isolate heteromeric GluA1/2 channels. Error
bars = SEM.was sensitive to the ratio of cotransfected GluA and TARP cDNA,
with saturating kainate efficacy requiring a GluA:TARP ratio of
1:5 for TARP g-8 (Figure S1 available online).
Kainate Efficacy Covaries with TARP/AMPAR
Stoichiometry
The observation that fusion of AMPARs and TARPs produces an
enhanced kainate efficacy comparable to coexpression of the
nonfused proteins raises the possibility that the channels formed
in the latter condition normally contain four TARP molecules.
However, it is also possible that fewer than four TARPs are suffi-
cient to saturate the effect of TARPs on kainate efficacy. To
address this possibility, we devised a method to measure the
properties of AMPARs that contain fewer than four TARP mole-
cules. While AMPARs that do not contain the GluA2 subunit are
readily blocked by the polyamine toxin philanthotoxin-433
(PhTx), those that do contain GluA2 are not. We reasoned that
coexpression of A1g-2 with nonfused GluA2 would produce
two populations of channels—those containing only GluA1 with
four TARPs, and those incorporating GluA2 and therefore con-
taining fewer than four TARPs. By including a concentration of
PhTx (600 nM) that blocks essentially all A1g-2 receptors
(Figure S2), we could block any four TARP channels and
measure the kainate efficacy of the isolated population of
GluA2-containing AMPARs with fewer than four associated
TARPs. Coexpression of A1g-2 with GluA2 (Figure 2C), as well
as the converse, GluA1+A2g-2 (Figure 2D), produced kainate
efficacies close to halfway between that of GluA1+GluA2, whichcontains no TARPs (Figure 2A) and A1g-2+A2g-2, which
contains four TARPs (Figure 2B). This establishes unambigu-
ously that AMPAR channels can be formed that contain fewer
than four TARP molecules, and that kainate efficacy covaries
with TARP/AMPAR stoichiometry. We obtained similar results
with fusion constructs between GluAs and TARP g-8, with four
TARP channels producing maximal kainate efficacy (Figure 2F),
and channels associated with fewer than four TARPs producing
roughly half the maximal kainate efficacy (Figures 2G and 2H). In
summary, functional AMPARs can be produced that contain
zero or four TARP molecules and, in addition, receptors can
form with an intermediate stoichiometry (Figure 2I). This estab-
lishes that kainate efficacy can be used to distinguish between
AMPARs with variable TARP/AMPAR stoichiometries.
What is the exact stoichiometry of the populations containing
fewer than four TARPs? The finding that these heteromers
formed by coexpression of GluAs with and without tethered
TARPs produce kainate efficacies intermediate between zero-
TARP and four-TARP channels suggests that they may contain
two TARPs. If there is an absolute requirement that heteromeric
AMPARs contain two GluA1s and two GluA2s when they are
coexpressed in vitro (Mansour et al., 2001), then all of the hetero-
mers would contain precisely two TARPs. If, on the other hand,
GluA1 and GluA2 assemble randomly (Washburn et al., 1997),
then coexpression of equal amounts of A1g-2 and GluA2 would
produce channels that predominantly contain two GluA2
subunits, but channels with other stoichiometries would also
be present. To distinguish between these possibilities, we variedNeuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc. 635
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the assembly of AMPARs toward channels that contain either
one or three GluA2s, and therefore three or one TARP, respec-
tively. To verify that altering the ratio of cotransfected cDNAs
actually results in surface expression of AMPARs with the ex-
pected subunit compositions, we measured the percent block
by PhTx of glutamate-evoked currents in outside-out patches.
When A1g-2 was expressed in 20-fold excess of GluA2, PhTx
blocked 90%, while the converse expression ratio produces
negligible block by PhTx, as predicted by either model of
assembly (Figure S3A).
Having confirmed that our cotransfection conditions indeed
vary the subunit composition of surface-expressed AMPARs,
we next isolated the GluA2-containing, heteromeric AMPAR
populations with PhTx and determined their kainate efficacies.
When expressing 20-fold more A1g-2 than GluA2, random
assembly would produce heteromeric channels that contain at
most one GluA2 subunit, and therefore three TARPs, while
assembly that prefers heterodimers would produce channels
that contain predominantly two GluA2 subunits, and therefore
two TARPs (Figure S3B). Consistent with the latter model, we
found that the kainate efficacy for this condition was identical
to that obtained with a transfection ratio of 3:2 (Figure 2J). Similar
results were obtained in the converse experiment expressing
20-fold more GluA2 than A1g-2 (Figure 2J). In this case, channels
containing four GluA2s and zero TARPs produce negligible
currents due to deficits in trafficking and low conductance (Bur-
nashev et al., 1992; Hollmann and Heinemann, 1994). Indeed, in
our conditions homomeric GluA2 receptors generated essen-
tially no current. The slight decrease in kainate efficacy observed
for this condition is intermediate between the values predicted
by the two assembly models (Figure S3B). This suggests that
under these extreme conditions, when GluA2 expression greatly
exceeds that of GluA1, it is possible for some channels to form
that contain three GluA2 subunits, but assembly is still strongly
biased toward formation of channels containing two GluA2 sub-
units. Comparison of the experimental data to values predicted
by various assembly models further rules out the potential com-
plication that kainate efficacy could be saturated for AMPARs
containing fewer than four bound TARPs (Figure S3B). These
experiments strongly suggest that, even under conditions that
should favor channels with assembly ratios of 1:3 or 3:1, GluA1
and GluA2 preferentially assemble at a ratio of 2:2, and that
the intermediate kainate efficacy observed when coexpressing
GluAs with and without fused TARPs reflects receptors that
predominantly contain two TARPs.
For experiments coexpressing GluA1+A2g-2, we expressed
GluA1 in excess (3:2) to minimize the chance of forming A2g-2
homomers, since there is no available pharmacology to block
these receptors. Under these conditions, 600 nM PhTx blocked
36% ± 8.3% (n = 7) of the glutamate currents (Figure S2D),
indicating the presence of GluA1 homomers in the plasma
membrane. In the presence of PhTx, the IKA/IGlu was 0.29 ± 0.03
(n = 9, Figures 2D and 2H), again suggesting that the remaining
heteromers contained two TARPs.
If coexpression of GluA1 and GluA2 results in preferential
formation of heterodimers, we wondered if by just coexpress-
ing fused and nonfused GluA2 we could force the assembly636 Neuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc.of channels that contain only one TARP. By coexpressing
GluA2 in excess of A2g-2, we predicted that random assembly
would prevail, producing either GluA2 homomers containing
zero TARPs that do not traffic or conduct, or channels that
incorporated one A2g-2 that could be assayed for kainate effi-
cacy. First we confirmed that expression of A2g-2 on its own
results in a high IKA/IGlu similar to A1g-2 (0.52 ± 0.04, n = 7),
consistent with a four-TARP receptor. Second, we confirmed
that expression of GluA2 did not produce currents in our condi-
tions. Surprisingly, when A2g-2 and GluA2 are expressed with
a 1:20 ratio, the resulting IKA/IGlu (0.38 ± 0.02, n = 7) is substan-
tially larger than would be expected for a one-TARP receptor.
This suggests that either GluA2 homomers containing one
TARP are not assembled, or they are unable to traffic or
conduct, similar to GluA2 homomers expressed in the absence
of TARPs.
TARP Stoichiometry Differs between Two Distinct
Types of Hippocampal Neurons
We sought to determine if the above results from HEK cells
could be compared with data from native AMPARs in neurons
in order to read out native TARP/AMPAR stoichiometry. First
we measured the kainate efficacy of AMPARs in outside-out
patches from mouse CA1 pyramidal neurons. These AMPARs
are predominantly (95%) GluA1/2 heteromers (Lu et al., 2009;
Zamanillo et al., 1999) associated with TARP g-8 (Rouach
et al., 2005; Tomita et al., 2003), and therefore can be directly
compared to the data we obtained expressing these GluAs
with TARP g-8. These native AMPARs displayed a high kainate
efficacy consistent with incorporation of four TARP molecules
per AMPAR complex (Figure 3A1 and 3C). However, while we
examined only the flip splice variant of AMPARs in HEK cells,
CA1 pyramidal neurons express both flip and flop variants of
AMPARs (Monyer et al., 1991). To determine if this might affect
the comparison, we repeated the experiments in CA3 pyramidal
neurons, which have been shown to express predominantly
flip variants (Monyer et al., 1991). These experiments yielded
a IKA/IGlu identical to that obtained in CA1 pyramidal neurons
(0.47 ± 0.04, n = 11), indicating that even if flop receptors exist
in CA1 pyramidal neurons, they do not substantially alter kainate
efficacy under our conditions. Furthermore, inclusion of the
compound PEPA, a drug that blocks the desensitization of flop
AMPARs (Sekiguchi et al., 1998), especially when associated
with TARPs (Tomita et al., 2006), had no effect on glutamate
responses in CA1 pyramidal neurons (Figure S4).
We further wondered if TARP/AMPAR stoichiometry could
be altered by genetic depletion or exogenous overexpression
of TARPs. Indeed, outside-out patches from TARP g-8+/ (Fig-
ure 3A2 and 3C) and TARP g-8
/ (Figures 3A3 and 3C) mice
revealed reduced kainate efficacy. However, overexpression
of either TARP g-8 (Figures 3A4 and 3C) or TARP g-2
(IKA/IGlu = 0.53 ± 0.03; n = 4, data not shown) did not substantially
increase kainate efficacy, supporting the notion that native
AMPARs in CA1 pyramidal neurons are normally saturated by
TARP expression, and therefore contain four TARPs per AMPAR
complex. The finding that overexpression of TARP g-2 does not
alter kainate efficacy differs from the results of Turetsky et al.
(2005). However, these authors specifically used immature
Neuron
TARP/AMPAR StoichiometryFigure 3. Kainate Efficacy in Extrasynaptic
AMPARs in Hippocampus Pyramidal
Neurons and Dentate Granule Neurons
(A) Hippocampal CA1 pyramidal neurons. (A1) In WT
animals, kainate-induced currents were about
half of that induced by glutamate. (A2) In TARP
g-8 heterozygote, the kainate efficacy was
reduced. (A3) In g-8 knockout (KO) mice the kai-
nate efficacy was further reduced. (A4) A sample
patch from g-8 overexpression (g-8 ov). Scale
bar: 2 s, 100 pA. (B) Dentate granule neurons.
(B1–4) Sample patches from granule neurons in
WT, g-8+/, and g-8/ and in a neuron overex-
pressing g-8. Scale bar: 2 s, 50 pA. (C) Summary
of IKA/IGlu. Pyramidal neurons: WT, 53.8% ±
2.0%, n = 11; g-8+/, 39.5% ± 1.2%, n = 17; KO,
19.8% ± 1.1%, n = 16; overexpression, 54.5% ±
2.5%, n = 8. Dentate granule neurons: WT,
37.3% ± 1.4%, n = 13; g-8+/, 31.7% ± 1.8%,
n = 11; g-8/, 27.9% ± 1.6%, n = 10; overexpres-
sion, 55.9% ± 2.0%, n = 9. The dashed lines indi-
cate the kainate efficacy of AMPARs expressed in
HEK cells. Note that kainate efficacy in WT pyra-
midal neurons is identical to that of four TARP
channels expressed in HEK cells, suggesting the
TARP stoichiometry is saturated in this neuronal
type. In contrast, kainate efficacy is drastically
lower in dentate granule neurons, indicating that
the TARP stoichiometry is unsaturated in granule
neurons. Also note that kainate efficacy in g-8
KO neurons is still bigger than those of apo-AM-
PAR in HEK cells, suggesting that the remaining
AMPARs are associated with non-g-8 TARPs. *p
< 0.05; **p < 0.01, compared to WT neurons. Error
bars = SEM. (D) Deactivation of AMPARs in
outside-out patches pulled from CA1 pyramidal
neurons. The patches were exposed to 1 mM
glutamate for 1 ms. The displayed currents were
averages of 10–15 traces and peak scaled. Scale
bar, 20 pA, 5 ms. The insert is the weighted t of
deactivation, which was slow in WT CA1 neurons
(3.83 ± 0.28 ms, n = 19), and significantly faster in g-8 KO neurons (2.82 ± 0.21 ms, n = 14, **p < 0.01). An intermediate deactivation was seen in g-8 heterozygous
(3.49 ± 0.26 ms, n = 18). The deactivation curves were well fit by a double exponential function, as shown in Table S1. Error bars = SEM.neurons in which TARP expression levels are low, likely contain-
ing AMPARs with reduced stoichiometry.
These data are in striking contrast to our previous findings
from cerebellar granule neurons, where the apparent TARP/
AMPAR stoichiometry was not saturated in wild-type neurons
(Milstein et al., 2007), and could be increased by overexpression
of TARP g-2. This raises the possibility that TARP/AMPAR
stoichiometry is a parameter that differs across neuronal cell
types. We tested this possibility by measuring kainate efficacy
in another neuronal population, hippocampal dentate gyrus
granule neurons. In situ data suggests that these neurons
express lower levels of TARP g-8 than CA1 or CA3 pyramidal
neurons do (Lein et al., 2007), and might be expected to display
reduced TARP/AMPAR stoichiometry. Indeed, wild-type granule
neurons exhibited a lower kainate efficacy than that observed in
CA1 pyramidal neurons (Figures 3B1 and 3C). Furthermore,
exogenous overexpression of TARP g-8 substantially increased
kainate efficacy in these neurons (Figures 3B4 and 3C), confirm-
ing that AMPARs are not saturated with TARPs in this cell type.
Importantly, the kainate efficacy observed when TARP g-8 wasoverexpressed was identical to that recorded in CA1 pyramidal
neurons, strongly implying that the pharmacological properties
of AMPARs in granule cells are the same as in CA1 pyramidal
neurons. Similar to pyramidal neurons, genetic depletion of
TARP g-8 further reduced kainate efficacy, with g-8+/ (Figures
3B2 and 3C) and g-8
/ (Figures 3B3 and 3C) mice exhibiting
reduced kainate efficacy relative to wild-type.
In this study we chose to use kainate efficacy as an assay to
probe the influence of TARP association on AMPAR function,
because of its ease and high sensitivity. However, more physio-
logically relevant parameters of AMPAR function are the kinetics
of channel deactivation and desensitization, which are known to
be influenced by TARP association (Priel et al., 2005; Tomita
et al., 2005; Turetsky et al., 2005). We therefore conducted
experiments in CA1 pyramidal neurons from TARP g-8 mutant
mice using fast application of glutamate to outside-out patches.
The time course of deactivation in control mice was similar to
that previously reported for rat neurons (Spruston et al., 1995)
(Figure 3D). However, in TARP g-8/ mice, AMPAR deactivation
was significantly faster, and it was intermediate in heterozygousNeuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc. 637
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TARP/AMPAR StoichiometryTARP g-8+/ mice (Figure 3D). The time course of AMPAR
desensitization similarly varied with TARP expression level
(Table S1 available online).
DISCUSSION
Since the discovery of TARPs a decade ago, numerous studies
have established that these auxiliary subunits control the traf-
ficking and gating of AMPARs, and that the magnitude of this
effect depends on the specific TARP subtype (Cho et al., 2007;
Kott et al., 2007; Milstein et al., 2007). Might the number of
TARP molecules that associate with individual AMPAR channels
also regulate gating? Although previous data raise this possibility
(Milstein et al., 2007), resolving TARP/AMPAR stoichiometry has
been surprisingly difficult. We have genetically linked TARPs to
AMPARs and have thus been able to identify the number of
TARPs associated with native AMPARs.
By expressing AMPAR subunits covalently linked to TARPs in
HEK cells, we have compared the properties of AMPARs con-
taining zero or four TARPs and receptors with an intermediate
stoichiometry. We show that kainate efficacy, previously shown
to increase with TARP association (Tomita et al., 2005; Turetsky
et al., 2005), varies with TARP/AMPAR stoichiometry and can be
used to distinguish between AMPARs that are saturated or
unsaturated by TARP expression. The functional effects of
TARPs g-2 and g-8 on fused GluA1 and GluA2 were similar,
and both varied with TARP/AMPAR stoichiometry. These results
not only establish that AMPARs can assemble with different
numbers of TARPs, but also provide valuable quantitative data
that can be compared to native AMPARs in neurons. Although
not addressed in this study, it would not be surprising if the
magnitude of other modulatory effects of TARPs, such as the
sensitivity of Ca2+-permeable AMPARs to block by intracellular
polyamines (Soto et al., 2007), and the trafficking of AMPARs
to synapses, might be similarly regulated by stoichiometry.
When we expressed heteromeric receptors in which only one of
the subunits was tethered to a TARP, we consistently obtained
receptors with a kainate efficacy that was roughly intermediate
between those observed with zero-TARP and four-TARP recep-
tors. This finding is consistent with the model in which AMPARs
are assembled with a stoichiometry of two GluA1 and two
GluA2 subunits (Mansour et al., 2001). If, however, subunits can
randomly assemble with a variable subunit stoichiometry (Wash-
burn et al., 1997), then the intermediate kainate efficacy could
represent a mixed population of heteromers with receptors con-
taining two TARPs predominating. Another possible interpreta-
tion of our results is that the kainate efficacy actually saturates
when fewer than four TARPs are bound to the receptor. Although
this would not alter the conclusion that stoichiometry can vary,
it would question the quantitative conclusions. However, a
simple set of calculations that predicts the kainate efficacies of
AMPARs that are produced by varying models of channel
assembly (Figure S3B) supports the scenario in which hetero-
dimer formation is preferred and the ratio saturates at four TARPs.
Remarkably, we find that AMPARs in CA1 pyramidal neurons
are normally associated with four molecules of TARP g-8.
When the expression level of g-8 is reduced, the number of
TARPs associated with each AMPAR is reduced. At this point638 Neuron 62, 633–640, June 11, 2009 ª2009 Elsevier Inc.we can only speculate as to what the precise TARP/AMPAR
stoichiometry is in g-8/ and g-8+/ mice. If we assume that
at least one TARP must be associated with AMPARs in order
for them to be efficiently trafficked to the cell surface, then we
would expect all surface receptors to contain at least one
TARP; indeed, the observed kainate efficacy of g-8/ pyramidal
neurons was between that expected for zero and two TARPs,
indicating that perhaps it is just one TARP. In this scenario,
TARPs g-2 and g-3, which are also expressed in pyramidal
neurons (Lein et al., 2007; Tomita et al., 2003), are associated
with the remaining AMPARs in g-8/ neurons. In addition, we
demonstrate in CA1 neurons that the time course of AMPAR
deactivation and desensitization varies with g-8 expression level,
consistent with the change of TARP/AMPAR stoichiometry.
Furthermore, we find that TARP/AMPAR stoichiometry differs
between distinct neuronal cell types. Unlike CA1 pyramidal
neurons, hippocampal dentate gyrus granule neurons are not
saturated with four TARPs, but instead appear to express a
mixed population of AMPARs containing fewer than four TARPs.
This is also consistent with the data we previously acquired from
cerebellar granule neurons (Milstein et al., 2007), and reinforces
the notion that differences in the expression level of different
TARP subtypes diversifies the functional properties of neuronal
AMPARs, not only through subtype-specific regulation, but
also through variable TARP/AMPAR stoichiometries.
EXPERIMENTAL PROCEDURES
cDNA and Constructs
cDNAs ofg-2,g-3,g-4,g-8, and flip-type GluA1 and GluA2 were used in current
study. The cDNAs were constructed into two vectors: pIRES2-EGFP and
pIRES2-dsRed (Clontech). GluA1 and all TARPs were subcloned with EcoR1
and Sal1 sites (Milstein et al., 2007). GluA2 was inserted with Xho1 and Sal1
sites. A Kozak sequence was engineered in front of the start codon. To
construct A1g-2, the following primers were used: forward primer, 50-GATC
TCGAGCTCGCCACCATGCCGTAC-30; reverse primer, 50-CCCGAATTCCTG
TTGCTGTTGCTGTTGCTGTTGCTGTTGCAATCCTGTGGCTCC-30. Standard
PCR was carried out with the GluA1 template and the product was inserted
into g-2-containing pIRES2 vectors with Xho1 and EcoR1 site, thus fusing
GluA1 to the N terminus of g-2 with a short linker sequence (Q)10EFAT. A1g-8,
A1g-3, and A1g-4 were constructed similarly. The primers used in constructing
A2g-2 and A2g-8 were as follows: forward primer, 50-GGACGCTAGCGC
CACCATGCAAAAGATTATGC-30; reverse primer, 50-GAGCTCGAGGACTGT
TGCTGTTGCTGTTGAATTTTAACACTCTCGATGCC-30. Nhe1 and Xho1 were
used to insert the PCR product. The linker sequence used between GluA2
and TARPs was (Q)6(S)5FEFAT. The constructs were verified with sequencing
(Elim). EGFP and/or dsRed fluorescence allowed visualization of coexpression.
Indeed, coexpression was observed in more than 90% of the positive
transfected cells.
HEK Cell Culture and Transfection
HEK cells were used for expression of GluAs, TARPs, and fusion constructs.
HEK cells were cultured in a 37C incubator supplied with 5% CO2 (Milstein
et al., 2007). Transfection was performed in 35 mm dishes or 6-well plates
with above cDNAs using lipofectomine2000 reagents according to the
protocol provided by the manufacturers (Invitrogen). The following strategies
were used in transfection if not otherwise specified. Total cDNA used for
transfection per 35 mm dish or per well in 6-well plates was 0.5 mg. When
expression was carried out, a 2:3 ratio of GluA to TARP cDNA was used,
except for A1+g-8, where 0.2 mg GluA1 and 5X or 10X g-8 were used. When
GluA1 (or fusion construct) and GluA2 (or fusion construct) were coexpressed,
the ratio of GluA1 to GluA2 was 3:2. Transfection was terminated in 2–3 hr.
Cells were dissociated with 0.05% trypsin and plated on coverslips pretreated
Neuron
TARP/AMPAR Stoichiometrywith poly-D-lysine. Recording was performed 24–48 hr after transfection. The
amplitude of glutamate-evoked currents varied considerably among HEK
cells. To determine if the amplitude of the glutamate current, which is presum-
ably due primarily to the number of receptors on the surface, had any effect on
the IKA/IGlu, we plotted the size of the glutamate current against the size of the
kainate current. The IKA/IGlu was entirely independent of the magnitude of the
glutamate-evoked current. (Figure S5).
Acute Hippocampus Slices and Slice Cultures
Transverse hippocampal slices 300 mm thick were cut from P14–P23 mice on
a Leica vibratome in cutting solution containing (in mM) NaCl 50, KCl 2.5, CaCl2
0.5, MgCl2 7, NaH2PO4 1.0, NaHCO3 25, glucose 10, and sucrose 150. Freshly
cut slices were placed in an incubating chamber containing artificial cerebro-
spinal fluid (ACSF), containing (in mM) NaCl 119, KCl 2.5, NaHCO3 26, Na2PO4
1, glucose 11, CaCl2 4, and MgCl2 4, and recovered at 35
C for 1 hr. Slices
were then maintained in ACSF at room temperature prior to recording. After
0.5–1 hr of incubation at room temperature, slices were transferred to a
submersion chamber on an upright Olympus microscope. All solutions were
saturated with 95% O2/5% CO2. CA1 pyramidal neurons were visualized by
Infrared differential interference contrast microscopy. Cultured slices were
prepared and transfected as previously described (Schnell et al., 2002). Briefly,
hippocampi were dissected from P6–P9 mice and transfected with g-8-IRES-
EGFP using biolistic gene transfer after 2–3 days in culture. Slices were
cultured for an additional 2–7 days before recording.
Electrophysiology
Outside-out patches were excised from transfected HEK cells or hippocampal
neurons in acute slices or slice cultures. Coverslips with transfected HEK cells
were maintained during recording with external solution containing (in mM)
NaCl 140, KCl 5, MgCl2 1.4, EGTA 5, HEPES 10, NaH2PO4 1, D-glucose 10,
and NBQX 0.01, with pH adjusted to 7.4. Outside-out patches were excised
from positively transfected cells identified by epifluorescence microscopy
with 3 to 5 MU borosilicate glass pipettes. The internal solution contained
(in mM) CsF 135, CsOH 33, MgCl2 2, CaCl2 1, EGTA 11, HEPES 10, and sper-
mine 0.1, with pH adjusted to 7.2. The glutamate- and kainate-induced currents
were recorded while holding the patches at –70 mV. Glutamate (1 mM) and kai-
nate (1 mM) were applied to patches in extracellular solution containing (in mM)
NaCl 150, KCl 2.5, HEPES 10, glucose 10, CaCl2 4, MgCl2 4, and Cyclothiazide
0.1, at pH 7.4. In addition, when GluA1/A2 channels with and without TARPs
were studied, 600 nM or 10 mM PhTx was included to block the potential
GluA1 homomeric channels (Figure S2). The hippocampal slices (acute or
culture) were perfused with ACSF bubbled with 5% CO2 and 95% O2. In slice
cultures, the cells with g-8 overexpression were visualized with EGFP fluores-
cence. Patches were excised from CA1 pyramidal neurons and dentate granule
neurons. The currents were recorded with pipette solution containing
CsMeSO4 135, NaCl 8, HEPES 10, Na3GTP 0.3, MgATP 4, EGTA 0.3, QX-314
5, and spermine 0.1. Glutamate and kainate were similarly dissolved in extracel-
lular solution with the addition of 100mM picrotoxin, 100mM D-APV, and 500 nM
tetrodotoxin to isolate AMPAR-mediated current. In fast application experi-
ments, the above extracellular solution (without cyclothiazide) was used for
control and glutamate dilution. Data were collected with an Axopatch 1D ampli-
fier (Axon Instruments, Foster City, CA), filtered at 2 kHz, and digitized at 10 kHz
for most patches and at 50 kHz for the fast application. Analysis of deactivation
and desensitization was described in a previous study (Milstein et al., 2007).
Data were presented as mean ± SEM. Differences in means were tested with
the ANOVA or Student’s t test and were accepted as significant if p% 0.05.
SUPPLEMENTAL DATA
Supplemental data for this article include one table and five figures and can be
found at http://www.neuron.org/supplemental/S0896-6273(09)00391-2.
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